June 13, 2020 - Bay Street News

NASDAQ Companies - June 13, 2020

Investigator-Initiated Study Shows Switching to Afrezza® Improves Glucose Control with No Additional Hypoglycemia in T2DM

WESTLAKE VILLAGE, Calif., June 13, 2020 (GLOBE NEWSWIRE) — MannKind Corporation (Nasdaq: MNKD) announced that data from a new clinical […]

NASDAQ Companies - June 13, 2020

Lexicon Pharmaceuticals Presents Clinical Data at 80th American Diabetes Association Scientific Sessions

THE WOODLANDS, Texas, June 13, 2020 (GLOBE NEWSWIRE) — Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today presented six posters for ZynquistaTM […]

NASDAQ Companies - June 13, 2020

Zealand Pharma presents elaborated results on the use of regular human insulin delivered by V-Go® in older adults with type 2 diabetes, at the 80th Scientific Sessions of the American Diabetes Association

Press release – No. 08 / 2020Zealand Pharma presents elaborated results on the use of regular human insulin delivered by […]

NASDAQ Companies - June 13, 2020

vTv Therapeutics Presents Two Late-Breaking Poster Sessions on Simplici-T1 Study at the American Diabetes Association’s Virtual Sessions Supporting the Potential of TTP399 as First-in-Class Oral Adjunctive Therapy for Type 1 Diabetes Patients

– Treatment with TTP399 resulted in significant improvements in HbA1c with reduction in insulin, without increasing risk of hypoglycemia or […]

NYSE Companies - June 13, 2020

Medtronic Shares Study Results on First of Its Kind Extended Wear Infusion Set from American Diabetes Association Conference

DUBLIN, June 13, 2020 (GLOBE NEWSWIRE) — Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced data on its […]

NASDAQ Companies - June 13, 2020

Zosano Pharma to showcase new post-hoc analyses of Qtrypta’s (M207) clinical trial data comparing key efficacy results from the pivotal study and the open-label long term safety study on the 2020 American Headache Society’s Virtual Annual Scientific Meeting Platform

FREMONT, Calif., June 13, 2020 (GLOBE NEWSWIRE) — Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that new […]